Bønløkke, S. E.
Rand, M. S.
Haddock, B.
Arup, S.
Smith, C. D.
Jensen, J. E. B.
Schwarz, P.
Hovind, P.
Oturai, P. S.
Jensen, L. T.
Møller, S.
Eiken, P.
Rubin, K. H.
Hitz, M. F.
Abrahamsen, B.
Jørgensen, N. R.
Article History
Received: 23 December 2021
Accepted: 31 May 2022
First Online: 21 June 2022
Declarations
:
: Niklas Rye Jørgensen declares that he has previously received assays as a donation from IDS Plc and Roche for research use but has no further conflict of interest. PE serves on the advisory board of UCB and Gedeon-Richter. BA reports speakers’ fees or consulting fees from Amgen, UCB, Kyowa-Kirin, Pharmacosmos, and Gedeon Richter and institutional research grants from UCB, Kyowa-Kiring, and Gedeon Richter. JEBJ reports advisory board membership in Eli Lilly, Amgen, Gedeon Richter, and UCB; received funding from Eli Lilly, Amgen, Alexion, and Samsung; and speaker’s fees from Eli Lilly, UCB, Amgen, Gedeon Richter, and Osaka. SEB, MSR, BH, SA, CDS, PH, PSO, LTJ, SM, KHR, and MFH have no conflicts of interest relevant to this study to declare.